{
    "root": "af6812a1-81c9-410f-bf97-59ebee0e6728",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Methylphenidate",
    "value": "20240329",
    "ingredients": [
        {
            "name": "METHYLPHENIDATE HYDROCHLORIDE",
            "code": "4B3SC438HI",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_31836"
        },
        {
            "name": "GELATIN, UNSPECIFIED",
            "code": "2G86QN327L",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_5291"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "DEXTROSE, UNSPECIFIED FORM",
            "code": "IY9XDZ35W2",
            "drugbank_id": "https://go.drugbank.com/drugs/DB09341"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32178"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "TRIETHYL CITRATE",
            "code": "8Z96QXD6UM",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_168426"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50821"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        }
    ],
    "indications": {
        "text": "methylphenidate hydrochloride extended-release capsules indicated treatment attention deficit hyperactivity disorder ( adhd ) , pediatric patients 6 12 years age [ ( 14 ) ] .",
        "doid_entities": [
            {
                "text": "attention deficit hyperactivity disorder (DOID:1094)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1094"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "\u2022 administer orally daily morning ( 2.2 ) . \u2022 capsules may swallowed whole opened entire contents sprinkled applesauce ( 2.2 ) . \u2022 crushed , chewed , divided ( 2.2 ) . \u2022 patients new methylphenidate : start 20 mg daily , titrating dose weekly 10-mg increments . doses 60 mg daily recommended ( 2.3 ) . \u2022 patients currently using methylphenidate hydrochloride tablets : based current dose regimen ( 2.4 ) . \u2022 switching methylphenidate products , discontinue treatment titrate methylphenidate hydrochloride extended release capsules ( 2.4 ) .",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "\u202210 mg extended-release capsules ( ndc 0781-2383-01 ) white/light brown , ( imprinted \u201c sdz r10 \u201d ) supplied bottles 100 \u202220 mg extended-release capsules ( ndc 0781-2384-01 ) white , ( imprinted \u201c sdz r20 \u201d ) supplied bottles 100 \u202230 mg extended-release capsules ( ndc 0781-2385-01 ) yellow , ( imprinted \u201c sdz r30 \u201d ) supplied bottles 100 \u202240 mg extended-release capsules ( ndc 0781-2386-01 ) light brown , ( imprinted \u201c sdz r40 \u201d ) supplied bottles 100 store 20\u00b0c 25\u00b0c ( 68\u00b0f 77\u00b0f ) ; excursions permitted 15\u00b0c 30\u00b0c ( 59\u00b0f 86\u00b0f ) [ usp controlled room temperature ] . dispense tight container ( usp ) .",
    "adverseReactions": "\u2022hypersensitivity methylphenidate components methylphenidate hydrochloride extended-release capsules . hypersensitivity , angioedema anaphylactic , reported patients treated methylphenidate [ ( 6.1 ) ] . \u2022concomitant treatment monoamine oxidase inhibitors ( maois ) , within 14 days following discontinuation treatment maoi , risk hypertensive crises [ ( 7.1 ) ] .",
    "indications_original": "Methylphenidate hydrochloride extended-release capsules are indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD), in pediatric patients 6 to 12 years of age [see Clinical Studies (14)].",
    "contraindications_original": "\u2022 Administer orally once daily in the morning ( 2.2 ). \u2022 Capsules may be swallowed whole or opened and the entire contents sprinkled on applesauce ( 2.2 ). \u2022 Should not be crushed, chewed, or divided ( 2.2 ). \u2022 Patients new to methylphenidate: Start at 20 mg daily, titrating the dose weekly in 10-mg increments. Doses above 60 mg daily are not recommended ( 2.3 ). \u2022 For patients currently using methylphenidate hydrochloride tablets: Dosage is based on current dose regimen ( 2.4 ). \u2022 If switching from other methylphenidate products, discontinue treatment and titrate with methylphenidate hydrochloride extended release capsules ( 2.4 ).",
    "warningsAndPrecautions_original": "\u202210 mg extended-release capsules (NDC 0781-2383-01) white/light brown, (imprinted \u201cSDZ R10\u201d) supplied in bottles of 100\n                     \n                        \u202220 mg extended-release capsules (NDC 0781-2384-01) white, (imprinted \u201cSDZ R20\u201d) supplied in bottles of 100\n                     \n                        \u202230 mg extended-release capsules (NDC 0781-2385-01) yellow, (imprinted \u201cSDZ R30\u201d) supplied in bottles of 100\n                     \n                        \u202240 mg extended-release capsules (NDC 0781-2386-01) light brown, (imprinted \u201cSDZ R40\u201d) supplied in bottles of 100\n                  \n                  Store at 20\u00b0C to 25\u00b0C (68\u00b0F to 77\u00b0F); excursions permitted between 15\u00b0C and 30\u00b0C (59\u00b0F and 86\u00b0F) [See USP controlled room temperature].\n                  Dispense in tight container (USP).",
    "adverseReactions_original": "\u2022Hypersensitivity to methylphenidate or other components of methylphenidate hydrochloride extended-release capsules. Hypersensitivity reactions, such as angioedema and anaphylactic reactions, have been reported in patients treated with methylphenidate [see Adverse Reactions (6.1)]. \n                     \n                        \u2022Concomitant treatment with monoamine oxidase inhibitors (MAOIs), or within 14 days following discontinuation of treatment with an MAOI, because of the risk of hypertensive crises [see Drug Interactions (7.1)].",
    "drug": [
        {
            "name": "Methylphenidate",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_6887"
        }
    ]
}